Healthcare Services

Increasing Incidence Of Melanoma To Fuel The Growth In Malignant Melanoma Treatment Market Continues To Impact The Growth Of The Malignant Melanoma Treatment Market

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Malignant Melanoma Treatment Market Change Between 2026 And 2030?

The malignant melanoma treatment market size has experienced rapid growth in recent years. It is projected to expand from $7.98 billion in 2025 to $8.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.1%. The expansion observed historically can be ascribed to a global rise in the incidence of skin cancer, heightened exposure to ultraviolet radiation, the early progression of chemotherapy-based melanoma treatments, increasing recognition of melanoma symptoms, and the initial efficacy of surgical melanoma management.

The malignant melanoma treatment market size is poised for substantial growth in the upcoming years. It is forecast to expand to $13.37 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.1%. This expansion during the forecast period is fueled by the increasing approval of advanced immunotherapies, a rising emphasis on personalized cancer treatment, augmented investment in oncology research and development, the broadening of melanoma screening programs, and improved healthcare access in emerging markets. Noteworthy trends anticipated in this period include the rising adoption of immunotherapy-based treatments, a greater utilization of combination treatment regimens, an intensified focus on early-stage melanoma intervention, the expansion of clinical trials for novel melanoma therapies, and a higher demand for specialized oncology care centers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13252&type=smp

Which Strategic Drivers Are Supporting The Malignant Melanoma Treatment Market Development?

A projected rise in melanoma incidence is anticipated to boost the malignant melanoma treatment market’s expansion going forward. Melanoma refers to a type of skin cancer originating in melanocytes, which are the skin cells producing pigment. Treatment strategies for melanoma frequently include surgical excision of the tumor, with supplementary therapies such as immunotherapy or targeted therapy potentially advised depending on the cancer’s stage and spread. For example, data from February 2023 provided by the Melanoma Research Foundation, a US-based entity, showed that the overall count of melanoma cases in the United States reached 1,87,000 in 2023. This figure saw a 7.3% rise, reaching 2,00,651 cases by 2024. Consequently, the growing frequency of melanoma is acting as a catalyst for the expansion of the malignant melanoma treatment market.

How Does Segment Analysis Break Down The Malignant Melanoma Treatment Market Structure?

The malignant melanoma treatment market covered in this report is segmented –

1) By Treatment: Immunotherapy, Radiation Therapy, Chemotherapy, Other Treatments

2) By Disease Type: Lentigo Maligna Melanoma, Acral Lentiginous Melanoma, Nodular Melanoma, Superficial Spreading Melanoma

3) By End-User: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Immunotherapy: Checkpoint Inhibitors, Cytokine Therapy, Oncolytic Virus Therapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Radiation Therapy

3) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens

4) By Other Treatments: Targeted Therapy, Surgical Interventions, Clinical Trials For Novel Therapies

What Trends Are Driving Changes In The Malignant Melanoma Treatment Market?

Key players within the malignant melanoma treatment market are concentrating on developing advanced solutions, such as autologous tumor-infiltrating lymphocyte (TIL) therapies. This focus aims to address the increasing demand for effective subsequent immunotherapies and personalized cell-based options for patients whose conditions worsen after receiving PD-1 inhibitors and targeted therapies. Autologous tumor-infiltrating lymphocyte (TIL) therapy involves collecting a patient’s own immune cells that have penetrated their tumor, multiplying them in a laboratory setting, and then reinfusing them into the patient to enhance the body’s ability to target and eliminate cancer cells. For instance, in February 2024, the US-based biopharmaceutical firm Iovance Biotherapeutics introduced AMTAGVI (lifileucel), an autologous TIL therapy. This treatment is intended for adults with melanoma that is either unresectable or metastatic, and who have not responded adequately to previous PD-1 therapy (and targeted therapy, if they have a BRAF V600-mutant). AMTAGVI (lifileucel) is composed of tumor-infiltrating lymphocytes, cultivated from the patient’s own tumor and administered after preparation; it works by boosting tumor-reactive T cells to facilitate the destruction of tumor cells. Key attributes of this therapy include its bespoke manufacturing process, a one-time administration approach, and its capacity to identify various tumor antigens.

Which Companies Are Engaged In The Malignant Melanoma Treatment Market Environment?

Major companies operating in the malignant melanoma treatment market are Johnson & Johnson Private Limited, Pfizer Inc., Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Mylan N.V., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Ono Pharmaceutical Co. Ltd., Exelixis Inc., Array BioPharma Inc., Pierre Fabre Group, Clinigen Group, Iovance Biotherapeutics Inc., X4 Pharmaceuticals Inc., Mirati Therapeutics Inc., Moleculin Biotech Inc., Polynoma LLC, Enzon Pharmaceuticals Inc., Northwest Biotherapeutics Inc.

Access The Complete Malignant Melanoma Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Which Region Commands The Largest Share Of The Malignant Melanoma Treatment Market?

North America was the largest region in the malignant melanoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant melanoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Malignant Melanoma Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13252&type=smp

Browse Through More Reports Similar to the Global Malignant Melanoma Treatment Market 2026, By The Business Research Company

Fertility Treatments Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Male Hypogonadism Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Fertility Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795